Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. (VTAK) is a U.S.-based medical device company focused on the cardiac electrophysiology market, and its news flow reflects developments around its VIVO 3D imaging system and LockeT suture retention device. The company’s releases highlight product adoption, regulatory milestones, financial updates, and corporate actions relevant to investors and clinicians following VTAK stock.
Recent news has emphasized international expansion for both VIVO and LockeT. Catheter Precision has reported tender wins and first purchase orders for the VIVO system at hospitals such as Albert Szent‑Györgyi Health Centre in Hungary and Dubrava University Hospital in Croatia, following evaluations against competing technologies. For LockeT, the company has announced launches in Switzerland and South Africa, distribution agreements with regional partners, and implementation at major electrophysiology centers, including Mater Private Hospital in Dublin, Ireland.
In addition to commercial updates, Catheter Precision issues releases on financial results, furnished on Form 8‑K, summarizing revenue trends and operating performance for specific quarters and year‑to‑date periods. The company also uses news announcements to discuss regulatory and reimbursement developments that may affect the use of its products, such as changes in procedure coverage for ambulatory surgery centers that it views as relevant to LockeT utilization.
Other news items cover intellectual property developments, including allowance of patents related to ventricular arrhythmia localization and neurostimulation devices, as well as corporate and capital markets events like reverse stock splits, at‑the‑market offering programs, and stockholder meetings. For ongoing insight into VTAK, this news page aggregates these updates so readers can follow Catheter Precision’s product adoption, geographic reach, financial disclosures, and key regulatory or governance events over time.
Catheter Precision announced a new purchase order for its medical device, LockeT, from Eisenhower Medical Center in Rancho Mirage, California. This marks the third hospital in California and the second in the U.S. to move beyond evaluation and approve orders for future use. The company has expanded its U.S. sales and clinical team to prepare for LockeT's national launch. LockeT aims to streamline procedures in operating and recovery rooms, potentially saving time and money. Chief Commercial Officer, Marie-Claude Jacques, expressed confidence in LockeT's growing recognition and the success of their commercial strategy.
Catheter Precision, Inc. (NYSE: VTAK) announced initial orders from Ronald Reagan UCLA Medical Center and Rady Children’s Hospital in San Diego for their newest product, LockeT. The company has expanded their US sales and clinical team in preparation for the national product launch, resulting in increased product evaluations and purchase orders.
Catheter Precision, Inc. (VTAK) has received a purchase order for LockeT, its newest product, from the University of California San Diego (UCSD) health system. This order allows for product evaluations at the hospital to begin. CEO David Jenkins emphasized the importance of hospitals evaluating products before committing to long-term purchases. VP Robert Locke praised UCSD as an early adopter of new technologies in electrophysiology.
Catheter Precision, Inc. (NYSE American: VTAK) released its Q1 2024 financials and operational report, highlighting key achievements and financial results. The company showcased progress in product development, clinical studies, and market expansion activities, along with a focus on talent acquisition to support future growth. With a solid financial position and a clear strategy, Catheter Precision aims to drive innovation in the field of cardiac electrophysiology.
Catheter Precision, Inc. (NYSE-American: VTAK) announces Marie-Claude Jacques as the new Chief Commercial Officer. With a background in successful sales leadership at Baylis Medical and Boston Scientific, Jacques aims to drive growth and success for Catheter Precision.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
